Developing New Treatments for Heart Failure: Focus on the Heart
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Compared with heart failure (HF) care 20 to 30 years ago, there has been tremendous advancement in therapy for ambulatory HF with reduced ejection fraction with the use of agents that block maladaptive neurohormonal pathways. However, during the past decade, with few notable exceptions, the frequency of successful drug development programs has fallen as most novel therapies have failed to offer incremental benefit or raised safety concerns (ie, hypotension). Moreover, no therapy has been approved specifically for HF with preserved ejection fraction or for worsening chronic HF (including acutely decompensated HF). Across the spectrum of HF, preliminary results from many phase II trials have been promising but are frequently followed by unsuccessful phase III studies, highlighting a disconnect in the translational process between basic science discovery, early drug development, and definitive clinical testing in pivotal trials. A major unmet need in HF drug development is the ability to identify homogeneous subsets of patients whose underlying disease is driven by a specific mechanism that can be targeted using a new therapeutic agent. Drug development strategies should increasingly consider therapies that facilitate reverse remodeling by directly targeting the heart itself rather than strictly focusing on agents that unload the heart or target systemic neurohormones. Advancements in cardiac imaging may allow for more focused and direct assessment of drug effects on the heart early in the drug development process. To better understand and address the array of challenges facing current HF drug development, so that future efforts may have a better chance for success, the Food and Drug Administration facilitated a meeting on February 17, 2015, which was attended by clinicians, researchers, regulators, and industry representatives. The following discussion summarizes the key takeaway dialogue from this meeting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957 · cited 2×
“successful phase III clinical trials with this population during the past decade have been rare.(1,3,4) Moreover, and perhaps”
BackgroundMethodIvabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563 · cited 1×
“successful phase III clinical trials with this population during the past decade have been rare.(1,3,4) Moreover, and perhaps”
MethodAnimal Models of Heart Failure: A Scientific Statement From the American Heart Association
Houser, S. R., Margulies, K. B., Murphy, A. M., Spinale, F. G., Francis, G. S., Prabhu, S. D., Rockman, H. A., Kass, D. A., Molkentin, J. D., Sussman, M. A., et al. (2012) · Circulation Research · doi:10.1161/res.0b013e3182582523 · Cited by 435
Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies
Vaduganathan, M., Butler, J., Pitt, B., & Gheorghiade, M. (2015) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.002271 · Cited by 38 · cited 3×
“Likewise, neprilysin inhibitors and agents that block the sympathetic and renin–angiontensin–aldosterone system may lower blood pressure as an intended or unintended consequence, and continued stepwise addition of novel hemodynamically active agents to target doses of existing therapies raises safety and tolerability…”
BackgroundInfluentialSelf-citation
Cited by
Mitochondrial function as a therapeutic target in heart failure
Brown, D. A., Perry, J. B., Allen, M. E., Sabbah, H. N., Stauffer, B. L., Shaikh, S. R., Cleland, J. G. F., Colucci, W. S., Butler, J., Voors, A. A., et al. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.203 · Cited by 803
Self-citationHuman cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity
Richards, D. J., Li, Y., Kerr, C. M., Yao, J., Beeson, G. C., Coyle, R. C., Chen, X., Jia, J., Damon, B., Wilson, R., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0539-4 · Cited by 439
Enabling Precision Cardiology Through Multiscale Biology and Systems Medicine
Johnson, K. W., Shameer, K., Glicksberg, B. S., Readhead, B., Sengupta, P. P., Björkegren, J. L. M., Kovacic, J. C., & Dudley, J. T. (2017) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.11.010 · Cited by 83
“The lack of proper measures that could be used for subset identification of HF patients has been implicated in the failure of recent HF trials (88,89).”
BackgroundBET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy
Antolic, A., Wakimoto, H., Jiao, Z., Gorham, J. M., DePalma, S. R., Lemieux, M. E., Conner, D. A., Lee, D. Y., Qi, J., Seidman, J. G., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.138687 · Cited by 41
Metadata
- Authors
- Gheorghiade, M., Larson, C. J., Shah, S. J., Greene, S. J., Cleland, J. G. F., Colucci, W. S., Dunnmon, P., Epstein, S. E., Kim, R. J., Parsey, R. V., Stockbridge, N., Carr, J., Dinh, W., Krahn, T., Kramer, F., Wahlander, K., Deckelbaum, L. I., Crandall, D., Okada, S., Senni, M., Sikora, S., Sabbah, H. N., & Butler, J.
- Venue
- Circulation: Heart Failure
- Published
- 2016-05
- Volume
- 9
- Issue
- 5
- ISSN
- 1941-3289 (ISSN-L)
- 1941-3297
- OpenAlex
- W2546982088
- Cited by
- 64
- References
- 4
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Developing New Treatments for Heart Failure: Focus on the Heart. https://app.cochat.ai/papers/10.1161/circheartfailure.115.002727
- The paper
- Gheorghiade, M., Larson, C. J., Shah, S. J., Greene, S. J., Cleland, J. G. F., Colucci, W. S., Dunnmon, P., Epstein, S. E., Kim, R. J., Parsey, R. V., Stockbridge, N., Carr, J., Dinh, W., Krahn, T., Kramer, F., Wahlander, K., Deckelbaum, L. I., Crandall, D., Okada, S., . . . Butler, J. (2016). Developing New Treatments for Heart Failure: Focus on the Heart. Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.115.002727
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.